Debanjana Chatterjee
Stock Analyst at JonesTrading
(4.97)
# 65
Out of 4,468 analysts
239
Total ratings
75.9%
Success rate
56.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Maintained: Buy | $26 → $31 | $7.61 | +307.36% | 16 | Jul 1, 2026 | |
| ATHE Alterity Therapeutics | Initiated Coverage: Buy | $16 | $5.36 | +198.51% | 1 | Jun 29, 2026 | |
| TBPH Theravance Biopharma | Downgraded: Hold | $19 → $17 | $16.93 | +0.41% | 12 | Jun 29, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $10 | $4.23 | +136.41% | 20 | Jun 25, 2026 | |
| ABCL AbCellera Biologics | Maintained: Buy | $13 | $8.11 | +60.30% | 5 | Jun 25, 2026 | |
| SION Sionna Therapeutics | Reiterated: Buy | $63 | $43.99 | +43.21% | 8 | Jun 25, 2026 | |
| ABSI Absci | Rated: Buy | $11 → $13 | $11.62 | +11.88% | 18 | Jun 24, 2026 | |
| EYPT EyePoint | Maintained: Buy | $43 | $13.98 | +207.58% | 25 | Jun 18, 2026 | |
| SYRE Spyre Therapeutics | Rated: Buy | $95 → $104 | $86.63 | +20.05% | 18 | Jun 16, 2026 | |
| PHVS Pharvaris | Maintained: Buy | $52 | $33.86 | +53.57% | 13 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.125 | - | 12 | May 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $5.89 | +239.56% | 5 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $17.56 | +65.15% | 27 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0285 | - | 8 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.02 | +494.06% | 16 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.41 | +193.26% | 3 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $15.10 | +72.19% | 10 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $17.93 | +33.85% | 21 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.57 | +218.47% | 1 | Apr 15, 2026 |
Sagimet Biosciences
Jul 1, 2026
Maintained: Buy
Price Target: $26 → $31
Current: $7.61
Upside: +307.36%
Alterity Therapeutics
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $16
Current: $5.36
Upside: +198.51%
Theravance Biopharma
Jun 29, 2026
Downgraded: Hold
Price Target: $19 → $17
Current: $16.93
Upside: +0.41%
Opus Genetics
Jun 25, 2026
Reiterated: Buy
Price Target: $10
Current: $4.23
Upside: +136.41%
AbCellera Biologics
Jun 25, 2026
Maintained: Buy
Price Target: $13
Current: $8.11
Upside: +60.30%
Sionna Therapeutics
Jun 25, 2026
Reiterated: Buy
Price Target: $63
Current: $43.99
Upside: +43.21%
Absci
Jun 24, 2026
Rated: Buy
Price Target: $11 → $13
Current: $11.62
Upside: +11.88%
EyePoint
Jun 18, 2026
Maintained: Buy
Price Target: $43
Current: $13.98
Upside: +207.58%
Spyre Therapeutics
Jun 16, 2026
Rated: Buy
Price Target: $95 → $104
Current: $86.63
Upside: +20.05%
Pharvaris
Jun 11, 2026
Maintained: Buy
Price Target: $52
Current: $33.86
Upside: +53.57%
May 29, 2026
Rated: Hold
Price Target: n/a
Current: $0.125
Upside: -
May 27, 2026
Reiterated: Buy
Price Target: $20
Current: $5.89
Upside: +239.56%
May 27, 2026
Reiterated: Buy
Price Target: $29
Current: $17.56
Upside: +65.15%
May 22, 2026
Rated: Hold
Price Target: n/a
Current: $0.0285
Upside: -
May 12, 2026
Reiterated: Buy
Price Target: $12
Current: $2.02
Upside: +494.06%
May 8, 2026
Maintained: Buy
Price Target: $10
Current: $3.41
Upside: +193.26%
May 8, 2026
Reiterated: Buy
Price Target: $26
Current: $15.10
Upside: +72.19%
May 6, 2026
Maintained: Buy
Price Target: $24
Current: $17.93
Upside: +33.85%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $5
Current: $1.57
Upside: +218.47%